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Storage of canine packed red blood cells (pRBCs) can increase erythrocyte
phosphatidylserine (PS) expression and eicosanoid concentrations. The objective of this
study was to determine the effects of leukoreduction on erythrocyte PS expression and
eicosanoid concentrations in stored units of canine pRBCs. Units of whole blood were
leukoreduced (LR) or non-leukoreduced (non-LR), and stored (10 and 21 days) as
pRBCs. Samples were collected at donation, and before and after a simulated
transfusion. PS expression was measured by flow cytometry, and concentrations of
arachidonic acid (AA), prostaglandin F2α (PGF2α), prostaglandin E2 (PGE2), prostaglandin
D2 (PGD2), thromboxane B2 (TXB2), 6-keto-prostaglandin F1α (6-keto-PGF1α) and
leukotriene B4 (LTB4) were quantified by liquid chromatography-mass spectrometry.
Our study demonstrated that PS expression on the surface of erythrocytes was not
affected by leukoreduction or storage duration. Additionally, the passage of blood
through a leukoreduction filter causes an immediate and dramatic increase in TXB2 and
PGF2α concentrations, but these concentrations then decrease during subsequent storage.

Despite leukoreduction, the concentration of 6-keto-PGF1α continued to increase during
storage and simulated transfusion. Overall, when compared to non-LR units, the addition
of a leukoreduction step prior to storage had a minimal impact on the accumulation of
eicosanoids in canine units of pRBCs. While leukoreduction may be beneficial in other
aspects of transfusion medicine, based on the results in this study, using leukoreduction
to decrease PS expression and eicosanoid concentrations does not appear to be effective.
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CHAPTER I
INTRODUCTION
History of Transfusion Medicine
Blood transfusions are commonly used for the treatment of life-threatening
anemia in today’s critical veterinary patients. Modern day blood transfusion techniques
were developed not in a single day’s achievement, but rather through a long journey and
contribution from many researchers. In humans, blood transfusions have been used as
life saving techniques for many, many years. In contrast, although the first blood
transfusion recorded was performed in a dog, veterinary transfusion medicine has
somewhat lagged, only significantly developing over the past several decades.
The first documented transfusion in any species occurred in 1665 when Richard Lower
withdrew blood from one dog and replaced it with blood from another dog. Over the
next several decades, transfusing of blood from animals to humans was described but
quickly outlawed due to the high rate of fatal reactions.1,2 It wasn’t until 1818, 150 years
after the first recorded canine transfusion, when James Blundell, a British obstetrician,
performed the first successful transfusion of human blood to a patient for the treatment of
postpartum hemorrhage. Using the patient's husband as a donor, he extracted a small
amount of blood from the husband's arm and, using a syringe, he successfully transfused
the wife. During the 19th and 20th centuries, human transfusion medicine exploded with
the development of sterile technique by Joseph Lister, the discovery of human blood

groups A, B and O by Karl Landsteiner, the establishment of anticoagulants, blood
banking systems and the American Red Cross as well as the development of stringent
blood storage and transfusion standards regulated by the Food and Drug Administration.2
Although much blood transfusion research was originally performed with
animals, veterinary transfusion medicine was not established until recently, most likely
secondary to shifting views of animals as companions rather than property, and the desire
for better animal health care. Due to the increasing availability of equipment and
facilities over the past several decades, transfusion of various blood products to
companion animals has become a common practice in not only advanced care facilities,
but general practices as well. As knowledge, has grown and the availability of different
blood products has increased, however, transfusion therapy has become more complex.
Blood from animal donors may be collected and immediately transfused, or
collected and stored for use in patients at a later date. Furthermore, blood can be
separated into different components, including but not limited to, packed red blood cells,
platelet concentrate, plasma and cryoprecipitate.3,4 Component products allow clinicians
to tailor-make treatment plans most appropriate for the individual patient. To further
increase the availability of blood products, storage of these products becomes necessary,
and can result in significant changes within the unit. These changes are known as
“storage lesions” and can contribute to reactions and decreased survival of the transfused
product within the recipient.5,6 Furthermore, several methods have been developed to
avoid these complications including cell washing and leukoreduction.6 This manuscript is
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intended to describe multiple aspects of veterinary transfusion medicine including
transfusion reactions, storage lesions and leukoreduction techniques.
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CHAPTER II
REVIEW OF THE LITERATURE
Transfusion Reactions
With the increasing availability of canine and feline blood products, transfusion
reactions are frequently encountered. Consequently, significant strides have been made
in the understanding of these reactions and how to limit their occurrence in our veterinary
patients. The incidence of transfusion reactions may vary depending on several factors
including storage time, storage techniques, underlying disease of the recipient, type of
product transfused and amount of product transfused. Currently, transfusion reactions
occur in 3-28% of canine and feline transfusions.1–6
Transfusion reactions can be categorized into acute and delayed, as well as
immunologic and non-immunologic in origin. Acute immunologic reactions include
febrile non-hemolytic reactions, acute hemolysis, allergic/anaphylactic reactions and
transfusion-related acute lung injury (TRALI). The most common types of acute
immunologic reactions include febrile non-hemolytic and allergic reactions however the
most life-threatening reaction encountered is acute hemolysis.7–10 Delayed immunologic
reactions may occur days to months following a transfusion. Types of delayed
immunologic reactions include hypersensitivity reactions II to IV which may manifest as
serum sickness, thrombocytopenia and/or shortened red blood cell life span.9,10

5

Immunologic reactions result from interactions between the recipients immune
system and a variety of cells, compounds and inflammatory mediators within the blood
product. Antibody-antigen interactions, especially directed against leukocytes and
platelets within blood products, can result in an increase in systemic levels of cytokines
and other pro-inflammatory mediators. Antibody binding to transfused mast cells and
basophils can lead to degranulation and secretion of pro-inflammatory and vasoactive
substances such as histamine, cytokines, and eicosanoids. The ability of transfusions to
modulate the recipient’s immune system is well established and characterized by the term
transfusion-related immunomodulation (TRIM).7,11,12 Underlying physiologic
mechanisms behind TRIM are multifactorial and determined not only by the
immunogenic potential of the transfused product, but also by the recipients underlying
disease process and genetic predisposition. The benefits of transfusion-induced
immunomodulation was first described in renal transplant recipients in which
immunosuppressive effects resulted in higher success rates.13 Deleterious effects have
since been described and are linked to manifestations such as viral activation, increased
occurrence of postoperative infection and TRALI.11,14 Described mechanisms by which
allogeneic transfusions may cause immunomodulation include depression of cellular
immunity by downregulation of T-helper type 1 and upregulation of T-helper type 2 cells,
dysregulation of innate immunity during inflammation by decreased natural killer cell
and macrophage function as well as neutrophil priming and endothelial cell
activation.11,15 The “two-insult” model of post-transfusion injury proposes that an initial
insult such an underlying inflammatory

6

condition or trauma primes the patient’s immune cells or endothelium, and further
inflammation is triggered by a second immunomodulating insult (eg, transfusion),
resulting in an unrestrained inflammatory response. This theory maybe the underlying
mechanism behind TRALI.14,16 Transfusion-related acute lung injury is the most
common cause of transfusion-related deaths in human, however, despite the theoretical
background for TRIM and TRALI, conclusive evidence of adverse clinical consequences
of immunomodulation is lacking in veterinary patients and warrants further investigation.
Regarding non-immunologic transfusion reactions, the most common include
infectious disease transmission, sepsis from bacterial contamination of the unit, citrate
toxicity leading to hypocalcemia (in patients receiving massive transfusions), and
circulatory overload.9,17 Typically, clinical signs of a transfusion reaction manifest early
in transfusion administration and may include fever, urticaria, facial edema, vomiting,
weakness, tachycardia or bradycardia, tachypnea, dyspnea, hypotension, hypothermia and
collapse.5,18 Signs consistent with a transfusion reaction can often be masked by the
clinical signs associated with the underlying immune mediated disease.3,5,10,17,18
With the expansion of veterinary transfusion medicine, standardized protocols
regarding product processing and storage, donor and recipient testing, product
administration and monitoring/treatment of reactions have been developed to best utilize
blood products while avoid transfusion reactions.19,20 Processing of veterinary blood
products primarily consists of sterile collection via a blood collection set into a storage
bag containing an anticoagulant preservative. Products may then be separated into
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components (such as fresh plasma, packed red blood cells, platelets concentration and
cryoprecipitate) or stored as whole blood. Each product may require a specific storage
environment and storage time. For example, whole blood is stored in a refrigerator at 4C
for a maximum of 35 days whereas fresh plasma may be frozen at -40C and stored for 1
year.9 Proper storage of blood products decreases the risk of both immunologic and nonimmunologic reactions.
Careful selection of donor animals should be performed. Perhaps the most
important criterion for donors is to meet minimum standards for infectious disease
testing. According to the most recent consensus statement regarding canine and feline
blood donor screening for blood-borne pathogens, minimal standards for dogs should
include a negative test result for Anaplasma platys and phagocytophilum PCR, Ehrlichia
canis PCR or serology, Babesia canis vogeli and Babesia gibsoni PCR, Bartonella
henselae and vinsonii subspecies berkhoffi PCR and Mycoplasma haemocanis PCR.
Minimal standards for cats include negative testing for Anaplasma phagocytophilum PCR
or serology, Bartonella henselae PCR, Mycoplasma haemofelis PCR, feline leukemia
virus antigen testing and feline immunodeficiency virus antibody testing. Infectious
agents for which testing is recommended are chosen based on the agents documented
ability to cause clinical infection in recipients after blood transmission, ability of the
agent to cause subclinical infection such that carriers might inadvertently be identified as
healthy blood donors, whether or not the agent can be detected using culture or molecular
methods from the blood of an infected animal, and finally, whether or not the resultant
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infection in the recipient has the potential to cause life-threatening illness and be difficult
to eliminate with antimicrobial drugs.21
Blood typing and cross matching are methods available to identify compatible
blood products prior to administration, in an effort to avoid immunologic reactions.
Canine blood types are characterized by the antigens present on the red blood cell. While
many canine antigens have been identified by sensitizing dogs with canine allogeneic
blood, only dog erythrocyte antigens (DEA) 1.1, 1.2, 3, 4, 5 and 7 can be routinely
measured.9 DEA 1.1 is highly antigenic and therefore can result in a severe hemolytic
transfusion reaction if DEA 1.1 positive blood is administered to a sensitized DEA 1.1
negative dog. Screening dogs for the presence or absence of this antigen is recommended
prior to transfusion.8,9 DEA 1.1 typing is readily available as a point-of-care test and the
Quick test DEA 1.1. The DEA 1.1 frequency of 42 to 71.2% varies with geographical
location and breed.8 Recently, another erythrocyte antigen, the Dal antigen has been
identified on canine red blood cells and can be absent in the Dalmation and Doberman
breed.22 Furthermore, Kai 1 and Kai 2 are two recent blood types discovered by
screening monoclonal antibodies. Discovery of Kai is the first discovery of canine blood
types by use of this technique.23 Feline blood types are determined by 3 alleles (A, ab and
b) with A being dominant over the rare ab, which is dominant over b. Cats with a genotype A/A, A/ab, or A/b are type A, whereas only cats with b/b are type B. Rare AB cats
are genotypically ab/ab or ab/b. Type A occurs in the majority (97%) of cats in the
United States while type B occurs in 0.3-6% of cats with a predilection for exotic breeds
such as the Devon rex (41%), British shorthair (36%), Cornish rex (31%), exotic
9

shorthair (27%), and Scottish fold (19%). Type AB appears to be rare and occurs in
approximately 1% of the cat population worldwide.24 Recently, a feline blood antigen,
termed Mik, has been identified and can play a role in blood incompatibility in cats that
lack this antigen.25
Cross matching enables identification of recipient antibodies to donor red blood
cells (major cross match) as well donor antibodies to recipient red blood cells (minor
cross match). Point-of-care cross matching kits are available for rapid determination of
blood compatibility. Current recommendations are that all donors and recipients should
be blood typed and cross matched prior to transfusion.8–10 In the canine species, an acute
reaction is less likely to occur in a recipient receiving a transfusion for the first time.
This is due to the lack of naturally-occurring alloantibodies against the majority of the
DEA groups; specifically, DEA 1.1 alloantibodies have not been observed in the
canine.26 Therefore, on an emergency basis only, forgoing typing and cross matching is a
viable option for dogs that have not received a prior transfusion or have not been
otherwise sensitized. In the cat, typing and ideally cross matching should always be
performed prior to a transfusion due to the presence of naturally-occurring alloantibodies
and high risk of a severe transfusion reaction in this species if incompatible blood is
administered.8,9 For cats, point-of-care testing will identify A or B blood. In summary,
with the majority of cases, pre-transfusion typing and cross matching should be
performed in order to provide the most compatible product for the recipient to limit the
risk of reaction and to limit antibody formation for future transfusions.
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Despite screening donors, providing adequate processing/storage methods and
identifying blood compatibility via typing and cross matching, transfusion reactions still
occur and are likely related to the presence and development of substances within the
blood product itself that can result in stimulation of the recipient’s immune system.
These immune-modulating substances include entire cells, cell particles, cytokines and
lipid mediators. They can be present at the time of collection of the blood product, such
as leukocytes and platelets, or may develop/accumulate during storage secondary to
altered metabolism, oxidative stress and accelerated product degradation. The latter,
termed storage lesions, are a subject of much research as they can be a significant
contributor to product survival as well as immune responses in the recipient.
Storage Lesions
The occurrence of a transfusion reaction within the recipient is multifactorial
however storage of blood products prior to administration has been associated with
increased risk of reaction as well as morbidity and mortality in the recipient.1,27,28 In an
effort to ensure adequate preservation of the units and safety to the recipient, standards of
canine and feline blood storage have been established and are largely based on human
protocols in which red blood cell products are stored for no longer than 42 days following
the Food and Drug Administration requirement that 75% of transfused red cells must
remain in circulation 24 hours after transfusion and hemolysis must affect less than 1% of
stored cells at the end of the storage period.19,20,29 Regardless of these protocols, changes
within the unit occur, and can be categorized into mechanical, biochemical and
immunologic events.12
11

Mechanical events include alterations secondary to physical manipulation of the
product including transient changes in ambient temperature, kinking of tubing, clogging
of filters, centrifugation or rough handling that results in shearing or lysis of cells,
damage to cellular membranes, decreased deformability of erythrocytes, increased
phosphatidylserine expression and microparticle formation. Mechanical events may
occur at any time, however most likely occur with increased incidence during handling
such as in collection of the product, product filtration or transfusion to the recipient.
Biochemical events occur during storage, and result from the artificial
environment in which the contents of the product are maintained. This artificial
environment results in altered metabolism and oxidative stress. Biochemical changes
include decreased adenosine triphosphate (ATP), 2,3 diphosphoglycerate (DPG) and
nitric oxide (NO), as well as increased potassium leakage, ammonia accumulation and
oxidative injury.
Because mammalian red blood cells do not contain mitochondria, they depend on
anaerobic glycolysis to produce two ATP and two lactic acid molecules per one glucose
molecule. An important enzyme in this pathway is phosphofructokinase which is
inhibited by the progressingly acidic environment in storage. As a result, ATP
production falls and results in membrane instability as well as failure of many
intracellular processes such as phosphorylation of membrane phospholipids and proteins,
membrane transport functions, synthesis of purine and pyrimidine nucleotides, and
synthesis of glutathione.12,30 Hemoglobin and 2,3 DPG bind resulting in reduced affinity
of hemoglobin for oxygen in erythrocytes, and allowing effective release of oxygen to
12

peripheral tissues.30 It is produced from a side pathway of anaerobic glycolysis and as a
result of decreased metabolism, 2,3DPG decreases in storage. Importantly however,
decreased 2,3 DPG has not been shown to affect oxygen delivery to the tissues when
transfused to rats.31 Nitric oxide is an uncharged radical produced by the vascular
endothelium and is a major endogenous vasodilator. Within red blood cells, NO binds to
a residue of hemoglobin to form S-nitrosohemoglobin (SNO-Hb). During storage,
erythrocyte SNO-Hb bioactivity falls rapidly and is not restored following infusion into a
recipient. It has been suggested that this may impair tissue oxygen delivery after RBC
transfusions.12,32 Oxidative reactions occur during normal metabolism and produce
reactive oxygen and nitrogen species. Naturally, these products are reduced and result in
minimal cellular injury. Mechanism to avoid oxidative injury depend largely on cellular
glutathione levels.30 In storage, decreased metabolism and ATP results in depleted
glutathione and progressive cellular injury and destruction.12,32 Through altered
metabolism, oxidative stress and cellular injury, levels of free hemoglobin, potassium and
ammonia increase in product supernatant.12 Free hemoglobin secondary to hemolysis and
hemoglobin-containing microparticles can react with NO after transfusion to form
methemoglobin and nitrate.33 The consequences of increased potassium and ammonia in
the supernatant of veterinary blood products is of uncertain significance and additional
research in this area is required.
Immunologic changes that occur in units during storage primarily result from
interaction with the white blood cell population.34 Leukocytes in packed red blood cell
units can become activated, producing and releasing pro-inflammatory cytokines such as
13

interleukin-8.35,36 Additionally leukocytes lyse early in storage and release enzymes that
not only result in damage to the erythrocyte but also contribute a portion of proinflammatory and pro-thrombotic compounds including elastase, secretory
phospholipase-A2, soluble FAS-ligand, prostaglandin E-2 and transforming growth
factor-1.37,38
Phosphatidylserine
An increase in phosphatidylserine (PS) expression on the red cell surface is a well
described red cell storage lesion of human blood products that results from
damage/degradation of the erythrocyte.39–41 Phosphatidylserine is a negatively charged
phospholipid, comprising a portion of the erythrocyte cell membrane. The majority of
cell membranes in the eukaryote, including the erythrocyte cell membrane, are comprised
of a lipid bilayer with neutral phospholipids (phosphatidylcholine and sphingomyelin) on
the outer leaflet of the cell membrane and negatively charged phospholipids
(phosphatidylserine, phosphatidylinositol and phosphatidylethanolamine) on the inner
surface.42
In circulation, as the erythrocyte ages or becomes damaged, alterations occur to
the cell membrane that allow for immune recognition and removal of the cell from
circulation via phagocytosis. One change of interest is PS translocating to the outer cell
membrane layer. At rest, PS is located within the inner leaflet of the plasma membrane,
but with aged or damaged erythrocytes, PS expression will gradually translocate to the
cell surface which will signal the need for cell removal via mononuclear phagocytic
cells.42 Consequently, in storage, the expression of PS on the surface of the red blood cell
14

serves as an indicator for erythrocyte health.43 Other changes that occur in the
aged/damaged erythrocyte includes an increase in senescent antigen formation, IgG
binding, loss of cell adhesion molecules, vesicle formation and loss of cell pliability.44,45
On average, a canine erythrocyte’s life span in circulation is 120 days, however,
in storage, erythrocyte degradation occurs at a faster rate. Phosphatidylserine expression
on the erythrocyte surface can be correlated to the availability of ATP. ATP allows
function of the enzyme aminophospholipid translocase which actively flips PS back to
the inner surface of the cells. Lack of ATP results in inadequate aminophospholipid
translocase activity and increased PS expression.46
During storage, erythrocytes are primed for ATP depletion and intracellular
potassium leakage which enhances PS expression on the erythrocyte surface.39
Furthermore, increased PS expression in units of packed red cells may promote
procoagulant activity. In other cell types, PS expression is involved in angiogenesis,
thrombin formation, and the regulation of vascular tone and can serve as a marker for
potential inflammatory and procoagulant activity.40,41,47 Phosphatidylserine-expressing
platelets in circulation play a pivotal role in activating the coagulation cascade.48
Phosphatidylserine-expressing erythrocytes do not appear to cause a similar effect,
possibly in part because senescent erythrocytes are cleared quickly from the circulation.40
In stored blood products, however, the amount of PS expression can accumulate and
potentially shorten the circulating survival time of the transfused erythrocyte, or
contribute to transfusion-related complications. In human research, Lu et al demonstrated
that increased erythrocyte PS expression in red blood cell concentrate is associated with
15

increased procoagulant activity, and that both the amount of PS expression and
procoagulant activity increased with the length of storage.41 Furthermore, leukoreduction
(removal of white blood cells and platelets) of whole blood prior to storage can decrease
this procoagulant activity.40,49,50
Several techniques have been developed to identify PS-expressing cells including
the use of chemical reagents or phospholipases to alter the externalized phospholipids,
techniques to monitor the redistribution of added phospholipid probe molecules across
the cell membrane, and the activation of hemostatic processes such as PS-mediated
activation of prothrombin to thrombin via prothrombinase.51,52
Flow cytometry is a technique available to identify and sort cell populations.
Using flow cytometry, PS-expressing erythrocytes can be identified and quantified by
using fluorescently labeled annexin V. Annexins are a family of proteins that bind to
charged phospholipids particularly PS. Fluorescently labeled annexins have been used to
identify PS on the surface of activated platelets under physiologic conditions in vitro as
well as on the surface of vesicles released from activated platelets and apoptotic cells.51,53
Radioactively labeled annexin V has been used to identify PS exposure in red cells.53
However, binding of radiolabeled annexin V only indicates the loss of phospholipid
asymmetry in the average cell and does not allow analysis of the erythrocyte population.
Kuypers et al. described the technique in human red blood cells showing that
fluorescently labeled annexin V used in conjunction with flow cytometry and fluorescent
microscopy offers an excellent method for the determination of loss of normal
phospholipid asymmetry in subpopulations or individual red cells.46
16

Eicosanoids
Eicosanoids are signaling molecules primarily derived from arachidonic acid.
Eicosanoids include the prostaglandins, leukotrienes and lipoxins and are involved in a
wide range of physiologic processes including the regulation of inflammation, vascular
and bronchial tone, platelet aggregation, uterine and gastrointestinal motility, and renal
blood flow as well as hypothalamic/pituitary hormone secretion.54 Eicosanoids play an
important role in modifying physiological processes in both homeostatic and
inflammatory condition via their interaction with signaling molecules such as cytokines
and chemokines.54 Furthermore, eicosanoids can modify inflammatory responses
depending on the type and location of the receptor to which they bind. Specifically,
thromboxane promotes platelet aggregation, vasoconstriction and bronchoconstriction.55
Thromboxane can also enhance the production of interleukin-8, a pro-inflammatory
cytokine and potent neutrophil chemoattractant55,56 Cys leukotrienes, those containing a
cysteine residue, specifically leukotriene B4, recruit neutrophils and other cells of
inflammation to site of tissue damage. Other leukotrienes (specifically, leukotriene D4)
trigger contractions in the smooth muscles lining the bronchioles and act in asthma and
allergic disease. Prostaglandin F2α (PGF2α) can regulate the cytokine response of mast
cells, while PGI2 is known to modulate immune cell functions, specifically T helper
cells.57,58 Lipoxins, which were the first eicosanoids to be identified and recognized as
potential anti-inflammatory mediators, are able to inhibit the production of IL-12 by
dendritic cells and modulate immunity against microorganisms.59
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Eicosanoids are synthesized from a wide range of cells including leukocytes, vascular
epithelial cells, and platelets. Although erythrocytes contain arachidonic acid (AA), they
do not possess the oxidative enzymes required for AA metabolism.60 Biosynthesis of
eicosanoids depends on the availability of AA which is produced from membrane
phospholipids by the action of phospholipase A2. Arachidonic acid can be metabolized
through three main pathways: the cyclooxygenase (COX) pathway producing the
prostanoids; the lipoxygenase (LO) pathway producing the leukotrienes and lipoxins and
the P-450 epoxygenase pathway producing hydroeicosatetraenoic acids (HETEs) and
epoxides.54 The pattern of eicosanoid production is determined in a stimulus and cellspecific fashion. All cell membranes of the eukaryote contain a rich source of
phospholipids and AA, however some cells, the erythrocyte for example, lack COX and
LO and therefore are incapable of production of most eicosanoids.
Transcellular biosynthesis is described as the cooperation of cells to produce
eicosanoids: one cell type is activated to synthesize an intermediate compound, through a
primary oxidative enzyme (COX or LO), that is transferred to a neighboring cell to carry
out the final synthesis. The second cell does not need to be activated, but can convert the
intermediate compound to the biologically active form by the presence of secondary
enzymes such as prostaglandin isomerases, LTA4 hydrolase or LTC4 synthase. For
example, LTA4 produced by neutrophils can be converted into LTC4 by vascular
epithelium or into LTB4 by erythrocytes. Also, PGI2 is produced from platelet derived
PGH2 by vascular epithelium or lymphocytes.54,60
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Multiple analytical techniques for quantitation of eicosanoids have been
developed and include immunoassays such as enzyme-linked immunosorbent assay
(ELISA) or radio-immunoassays (RIA), and gas chromatography (GC) or liquid
chromatography (LC) coupled to mass spectrometry (MS) or tandem mass spectrometry
(MS-MS).61–63 Immunoassays provide excellent sensitivity but can only be used for the
quantification of single analytes, and are susceptible to cross-reactions. These
impairments are overcome by GC-MS or GC-MS-MS, but these methodologies are labor
intense and time consuming due to the requirement of derivatization prior to analysis.
LC-MS-MS based methods have become highly valuable in the measurement of various
eicosanoids and other chemicals in biological samples because of their high sensitivity,
high selectivity and simplicity of sample preparation.64–67
While there is little information in human literature and even less in veterinary
literature regarding eicosanoids and stored blood products, some reports have
documented that certain eicosanoids and other lipids accumulate with prolonged storage.
In a previous study, our research group has demonstrated a significant increase in an
array of eicosanoids during storage and transfusion of canine packed red blood cells.68
Similarly, Jacobi et al demonstrated that prostaglandin E2 (PGE2) and thromboxane B2
(TXB2) increased during storage, but stated these levels remained within physiologic
limits and likely do not contribute to the risk of immunomodulated transfusion
reactions.69 Spinelli et al, demonstrated that PGE2 and TXB2 levels increased with
storage, and that leukoreduction prior to storage significantly decreased TXB2
accumulation and, to a lesser degree, PGE2 as well.70 Since leukocytes and platelets are
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primarily responsible for the production of eicosanoids within stored blood products, it is
reasonable to assume that leukoreduction may serve to decrease eicosanoid accumulation.
Recently however, other human reports have linked accumulation of biologically active
lipids, including arachidonic acid, in stored whole blood with transfusion-related acute
lung injury (TRALI) even in units that have been leukoreduced.15
Transfusion-related acute lung injury has been linked to a number of mediators
including biologically active lipids. Silliman et al, provide evidence that bioactive lipids
that accumulate during storage may contribute to TRALI as a result of neutrophil
priming. Lipids identified in that study included nonpolar lipids such as arachidonic acid,
HETE, 12-HETE and 15-HETE. These lipids accumulate in red blood cell concentrates
and therefore it is presumed they can be produced from peroxidation in addition to
enzymatic conversion from arachidonic acid.15 Lysophosphatidylcholine (lyso-PC) is
another lipid derived from phospholipid membranes that can accumulate in storage and
prime neutrophils. Both the non-polar lipids and lyso-PCs accumulate despite removing
the platelet and leukocyte population and therefore the risk of TRALI is not completely
diminished by the process of leukoreduction.16,71 Although no veterinary studies have
evaluated lipids and their role in transfusion reactions, it is reasonable to believe these
lipids can accumulate in companion animal blood products as well. Further studies are
needed to identify these lipids as well as to evaluate whether storage conditions can affect
their concentrations.

20

Efforts to Reduce Storage Lesions
Storage lesions can be minimized by specific processing procedures either before
storage or immediately prior to transfusion to the recipient. These procedures include
leukoreduction prior to or after storage, post-storage cell washing, and rejuvenation prior
to administration.12 With leukoreduction prior to storage, the majority of leukocytes and
platelets are extracted from the unit of blood via passage through a specialized filter,
preventing these cells from influencing the environment within the unit and reducing the
inflammatory response associated with blood transfusion in the recipient.27 Pre-storage
leukoreduction has been shown in veterinary medicine to effectively remove 99% of
donor leukocytes.72 Despite this, leukoreduction is not commonly performed in veterinary
clinics. This is most likely due to decreased availability and a lack of knowledge
regarding whether leukoreduction is beneficial in companion animals. In units of stored
human packed red blood cells, the removal of leukocytes and platelets via specialized
leukoreduction filters prior to storage results in a significant reduction in PS expression
on erythrocytes.40 In veterinary medicine, Herring et al, determined that PS expression on
microparticles can be identified in canine whole blood, and that leukoreduction will
attenuate the expression of PS on microparticles.73 However, in that study, because
microparticle PS expression was measured, it is unclear from which cell line PS
originated. Currently, it is unknown how leukoreduction and storage will affect the
expression of PS directly on the canine red blood cell. While leukoreduction removes the
leukocyte and platelet population, it can still leave behind microparticles, free
hemoglobin and inflammatory mediators. Additionally, levels of thromboxane B2 can
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increase during the leukoreduction process, which may be relevant when blood products
are leukoreduced post-storage and immediately administered to the recipient.74 This
technique is no longer recommended in humans due to subsequent hypotension.75
Alternatively, post-storage washing of RBCs prior to transfusion may help remove
products left behind from leukoreduction. During the washing process, saline is added to
erythrocyte units then the units are centrifuged and the supernatant is removed. Several
human studies have proven the benefit of washing units prior to transfusion including a
reduction in inflammatory markers.76–80 Additional research is needed in veterinary
medicine to assess the potential benefit of post-storage washing. Rejuvenation is another
post-storage method developed to address storage lesions. During rejuvenation, a solution
containing inosine, phosphate, and adenine is added to stored erythrocyte units prior to
transfusion to restore RBC morphology, ATP, and 2,3 DPG concentrations. Rejuvenation
appears to be beneficial in human research, however studies are lacking in companion
animals.81,82 Overall, strategies to minimize storage lesions have proven beneficial in
human medicine. This may translate similarly to veterinary medicine however cost
versus benefit must be considered in companion animals.
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CHAPTER III
Effect of leukoreduction and storage on erythrocyte phosphatidylserine expression and
eicosanoid concentrations in units of canine packed red blood cells.
Introduction
Blood transfusions are commonly used for the treatment of anemia in critical
veterinary patients. Storage of blood products, although necessary, creates an unnatural
environment that can lead to accelerated product degradation.1 In humans and dogs, a
direct correlation has been established between blood product storage time and increased
morbidity and mortality in transfused patients, suggesting that stored blood products can
undergo significant changes that lead to an increased risk of complications in the
recipient.2-7 Numerous studies have investigated red blood cell storage lesions, and
several mechanisms have been identified as contributors to the degradation of stored
erythrocytes.1,4,8
In humans, an increase in phosphatidylserine (PS) expression on the red cell surface
is one recognized storage lesion.9-11 Phosphatidylserine is a negatively charged
phospholipid, comprising a portion of the erythrocyte cell membrane. Normally, PS is
confined to the inner leaflet of the erythrocyte cell membrane but, in aged or damaged
erythrocytes, PS will translocate to the cell surface and serve as an indicator of
erythrocyte quality. An increase in expression of erythrocyte PS will signal the need for
cell removal via mononuclear phagocytic cells, potentially decreasing the life span of
transfused erythrocytes. 9, 12-14
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Recently, it has been demonstrated that there is a significant accumulation of
eicosanoids, such as prostaglandin F2α (PGF2α), leukotriene B4 (LTB4), thromboxane B2
(TXB2), and 6-keto-prostaglandin F1α (6-keto-PGF1α, a stable prostacyclin metabolite), in
units of canine packed red blood cells (pRBCs) during storage and transfusion.15
Eicosanoids are signaling molecules derived from arachidonic acid. These molecules are
involved in a wide range of physiologic processes that include maintenance of vascular
and bronchial tone, platelet aggregation, gastrointestinal motility, and renal blood flow.
Additionally, eicosanoids can modulate the inflammatory response via the interaction
with signaling molecules, cytokines and chemokines,16 potentially contributing to the
development of transfusion reactions. Although it is unknown how eicosanoids within
blood products will affect the recipient during a transfusion, the infusion of prostacyclin
in dogs has been shown to cause immediate and dramatic vasodilation.17 Additionally,
other eicosanoids within blood products, such as thromboxane, which causes platelet
activation and vasoconstriction, could adversely affect the transfusion recipient.
Eicosanoids are synthesized from a wide range of cells, including leukocytes,
vascular epithelial cells and platelets. Although erythrocytes contain arachidonic acid,
they do not possess the oxidative enzymes involved in arachidonic acid metabolism and
eicosanoid synthesis.18 The leukocyte and platelet populations inside units of pRBCs are
probably the major contributors to arachidonic acid metabolism.15 In humans, leukocytes
will lyse early in storage, releasing enzymes that can damage the erythrocyte, causing an
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increase in PS expression, and contribute to the synthesis of proinflammatory molecules,
including phospholipaseA2, which can contribute to eicosanoid production.4,19 With the
use a leukoreduction filter prior to storage, the majority of leukocytes and platelets are
extracted from the unit of blood, preventing these cells from influencing the environment
inside the pRBC unit, and reducing the inflammatory response associated with
transfusions.20 In units of stored human pRBCs, the removal of leukocytes and platelets
via leukoreduction prior to storage causes a significant reduction in erythrocyte PS
expression.10 Reduction in concentrations of leukocytes and platelets within the unit also
removes the main source of eicosanoid synthesis.
Currently, it is unknown how leukoreduction and storage will affect erythrocyte
PS expression and eicosanoid concentrations in units of canine pRBCs. The objective of
this study was to determine the effects of leukoreduction on erythrocyte PS expression
and eicosanoids that accumulate in units of canine pRBCs after storage and transfusion.
Our hypothesis was that the use of a leukoreduction filter to eliminate the majority of
leukocytes and platelets from pRBCs prior to storage would significantly decrease
erythrocyte PS expression and eicosanoid concentrations.
Materials and Methods
Animals
Dogs were chosen from our research colony and included in the study if they were
determined to have normal health status and they were not exposed to any medications or
vaccines for at least 2 weeks prior to initiation of the study. Normal health status was
established by detection of no abnormalities on physical examination, complete blood
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count, serum chemistry, urinalysis, and heartworm and tick-borne disease testing. Animal
use was approved by the Mississippi State University Institutional Animal Care and Use
Committee and was in compliance with the requirements of a facility accredited by the
American Association for Accreditation of Laboratory Animal Care.
Blood Donation, Leukoreduction, and Sample Collection
The donors were randomly separated into one of two groups, a leukoreduction
(LR) group and a non-leukoreduction (non-LR) group. Each dog underwent a standard
blood donation. Briefly, the donors were positioned in either right or left lateral
recumbency, and the fur overlying the jugular vein was clipped and the skin aseptically
prepared. A 16-gauge needle was inserted into the jugular vein and approximately 450
milliliters of blood was collected aseptically, under negative pressure, into a standard
triple blood banking baga for the non-LR group and a quadruple blood banking bagb,
containing a leukoreduction filter, for the LR group. The units contained an anticoagulant
citrate phosphate dextrose solution. There were no adverse events detected in the donor
dogs during or after blood collection.
For the LR group, the unit was leukoreduced and platelet-depleted by passage of
blood through a leukoreduction filter directly after collection. To assess the extent of
leukoreduction, blood samples were collected before and after leukoreduction from the
in-line tubing system for a total leukocyte and platelet count using an automated
hematologic analyzer.c For both LR and non-LR groups, pRBCs were created by
separating the red cells and plasma via centrifugation. To remove the plasma following
centrifugation, external pressure was applied to the blood bag, and the plasma was passed
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via a connecting tube into an attached empty bag for subsequent storage as fresh frozen
plasma. While still containing plasma, the connecting tube between the two blood bags
was sealed and removed. The plasma in the sealed tube was collected, snap frozen in
liquid nitrogen, and stored at -80oC. This plasma represented the initial sample
(“donation sample”) for eicosanoid analysis. The remaining unit of pRBC was
separated, to create two half units, by applying external pressure to the unit and allowing
erythrocytes to pass, via a connecting tube, into an attached empty bag. While still
containing red blood cells, the connecting tube between the two blood bags was sealed
and used as the initial sample (“donation sample”) for PS expression. Each half unit of
pRBCs was stored vertically at 4oC in a dedicated refrigerator for 10 or 21 days. The
donors underwent at least a 28-day recovery period after blood collection, switched
groups and the process was repeated.
On Day 10 of storage, one half unit from each dog (4 LR and 4 non-LR) was
removed and samples were collected for analysis. When removed from refrigeration,
each half unit was infused with 50 mL of 0.9% saline, mixed gently, and 1 mL of
reconstituted packed red blood cells was removed from the unit for measure of PS
expression. An additional 20 mL of reconstituted packed red blood cells were collected,
centrifuged, and the supernatant was removed for eicosanoid analysis. This sample was
snap frozen in liquid nitrogen and stored at -80oC until analysis. The collected
erythrocytes and supernatant represented the “Day 10 pre-transfusion” samples. To
mimic transfusion conditions, the remainder of each half unit was left at room
temperature for 5 hours. At the completion of this time period, using the same procedures
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as mentioned above, a 1 mL sample was collected and processed for the measurement of
erythrocyte PS expression, and a 20 mL sample was collected for eicosanoid analysis.
The collected erythrocytes and supernatant represented the “Day 10 post-transfusion”
samples. On Day 21 of storage, the 8 half units of pRBCs that had remained in
refrigeration were removed and processed similar to the Day 10 samples. The
erythrocytes and supernatant collected on Day 21 of storage represented the “Day 21 pretransfusion” and “Day 21 post-transfusion” samples.
Phosphatidylserine Analysis
A flow cytometric assay was used to quantitate the expression of PS on canine
erythrocytes. Labeling of cells was performed based on a previously described
protocol.21 Personnel performing flow cytometry were blinded to knowledge of whether
samples were LR or non-LR. For red blood cell preparation, 50 µL of concentrated
erythrocytes were washed twice with FACS-PBS, containing 0.2% bovine serum
albumind, and 10 µL of the washed red blood cells were resuspended in 90 µL of FACSPBS. For flow cytometric analysis, 16 µL of washed RBCs were incubated with
annexin-V-FITCe and annexin binding buffer for 15 minutes in the dark at room
temperature. After incubation, 400 µL of annexin binding buffer was added, gently
mixed, and analyzed within one hour. Flow cytometric analysis was performed with a
flow cytometerf and computer software.g Red blood cell populations were displayed on
log forward-scatter versus log side-angle light scatter plots. Gates were adjusted to
baseline erythrocyte populations, and 5,000 gated events were recorded for each labeling.
For quality control, both positive and negative controls were included. Expression was
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quantified by the intensity of annexin-V-FITC fluorescence and expressed as median
fluorescence intensity (MFI).
Eicosanoid Analysis
Using a previously established technique,22 the concentrations of arachidonic acid (AA),
prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), PGF2α, TXB2 (a stable metabolite of
thromboxane A2), 6-keto-PGF1α (a stable, hydrolyzed product of prostacyclin (PGI2)) and
LTB4 were analyzed by liquid chromatography-mass spectrometry. Personnel performing
spectrometry were blinded to knowledge of whether samples were LR or non-LR. The
thawed plasma/saline supernatant, which contained deuterated internal standards (d4-8iso PGF2α, d4-LTB4, and d8-arachidonic acid), were extracted by using C18 SepPak
columns.h After drying, 10 μl of the resolubilized lipids was injected onto an Acquity
UPLC BEH C18 column (1.7 µm, 100 ×2.1mm I.D.).i The analytes were eluted from the
analytical column with a gradient program and directed into a mass spectrometer.j The
concentrations were determined by measuring the area under the chromatographic peak
and comparing this value to the area under the chromatographic peak for the internal
standard. A computer software programk was employed for data acquisition and
processing. The eicosanoid concentrations were normalized to the volume of plasma
used for analysis and expressed as pmol/ml plasma. The estimated limits of detection
with this protocol are between 0.1-10 nM on-column.
Statistical Analysis
Sample size calculation was performed based on previously published data.15 The
assumptions used in the calculations were an alpha of 0.05 and a power of 0.95. An
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estimated sample size of 8 dogs would detect if the concentrations of 6-keto-PGF1α and
TXB2 following leukoreduction would be similar to the initial donation sample. A linear
mixed model was fit with PROC MIXED in a statistical software programl for the each
outcome. Run, sequence, filter, sample, and the filter and sample interaction were
included as fixed effects with a Kenward-Rogers degrees of freedom method specified.
Dog identity was included as random effect with a variance component covariance
structure specified. Repeated measures of dog identity within run for the different
samples were specified in a repeated statement with a spatial power law covariance
structure. The interaction term was dropped from the model if it was not significant. If
the interaction term was significant, differences in least squares means between each of
the concentrations of one variable were calculated for each concentration of the other
variable in the interaction using an LSMESTIMATE statement. The simulate adjustment
for multiple comparisons was used for significant effects. The distribution of the
conditional residuals was evaluated for each outcome to ensure the assumptions of the
statistical model had been met. An alpha level of 0.05 was used to determine statistical
significance for all methods.
Results
Animals
Eight healthy adult research Walker Hound dogs, five males and three females,
were used in this study. The mean age of the dogs was 1.5 years (range, 1.5 to 6.5 years),
and their mean body weight was 27.4 kg (range, 20.5 to 30.5 kg).
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Leukoreduction
The leukocyte and platelet counts prior to and after leukoreduction are
represented in Figure 1. Leukoreduction was effective at removing all leukocytes,
however, although leukoreduction was effective at removing 98.3% of the platelets in 7
of the 8 units, but there was only a partial reduction in platelet count (59.7%) in one unit.
Phosphatidylserine Expression
The MFI of erythrocyte PS expression is summarized in Table 1. Compared to
the respective donation sample, there was no significant changes in the MFI at any time
point for the non-LR units and the LR units. Additionally, when comparing the MFI
between the non-LR and LR units, there were no significant differences at any time
points.
Eicosanoid Concentration
The eicosanoid concentrations for the non-LR and LR units at all time points are
represented in Table 2. There was no difference in AA, PGE2, PGD2, and LTB4
concentrations at any time point, nor was there a difference in the concentrations between
non-LR and LR units.
At the time of donation, the PGF2α concentrations in LR units were significantly
(p<0.0001) greater than non-LR units. PGF2α concentrations in LR units then dropped
rapidly with storage, such that there was no difference in PGF2α concentration between
the LR and non-LR units for any of the remaining time points. For the LR-units, the
PGF2α concentration in all of the subsequent samples, pre and post transfusion, were
significantly (p<0.01) less than the initial donation sample. There was no significant
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difference in PGF2α concentration among the pre and post transfusion samples collected
from the LR units on Days 10 and 21. There was no difference in PGF2α concentration
among the samples collected from the non-LR units.
At the time of donation, the TXB2 concentrations in LR units were significantly
(p<0.0001) greater than non-LR units. TXB2 concentrations in LR units then dropped
rapidly with storage, such that there was no difference in TXB2 concentration between
the LR and non-LR units for any of the remaining time points. The TXB2 concentration
in all LR samples, except for Day 10 post-transfusion, was significantly (p<0.05)
decreased compared to the donation sample. There was no significant difference in TXB2
concentration among the pre and post transfusion samples collected from the LR units on
Days 10 and 21. There was no difference in TXB2 concentration among the samples
collected from the non-LR units.
When compared to the initial donation sample, there was a significant (p<0.0001)
increase in 6-keto-PGF1α concentrations irrespective of unit type for both LR and non-LR
units on both Days 10 and 21 for both the pre and post transfusion samples. The day 10
post transfusion sample concentrations were significantly greater (p=0.0029) than the day
21 pre transfusion samples, irrespective of unit type. The 6-keto-PGF1α concentrations
for the LR units were significantly increased (p=0.0163) compared to the non-LR unit
concentrations, irrespective of sample time.
Discussion
Transfusion with stored blood products has been associated with an increase in
morbidity and mortality in transfused patients, compared to transfusion with fresh
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products.2-8 In human medicine, increased PS expression on the red blood cell surface
and the accumulation of eicosanoids inside the stored unit are proposed mechanisms that
contribute to the degradation of stored erythrocytes and transfusion reactions.9-11, 23 With
the use a leukoreduction filter prior to storage, removing the majority of the leukocytes
and platelets from the unit, the environment inside the unit is thought to be less conducive
for the formation of storage lesions, which is proposed to reduce the inflammatory
response and reactions associated with transfusions.20 The results of our study
demonstrate that, in units of canine pRBCs, leukoreduction and storage have minimal
impact of erythrocyte PS expression, but alter concentrations of some eicosanoids.
Based on our study, erythrocyte PS expression was not altered by leukoreduction,
length of storage, or simulated transfusion. Similar findings have been reported in human
studies, in which only a small percentage of PS-positive erythrocytes (3.5 to 4.5%) were
detected after prolonged storage times of up to 7 weeks using similar techniques.11,24-26
One possible explanation for why an increase in RBC PS expression was not detected is
that the PS positive portions of the erythrocyte membrane were released from the cell and
became microparticles in the unit. In stored units of human pRBCs, erythrocytes can
undergo vesiculation to return to a PS-negative state by shedding PS-containing
vesicles.9,27 It is unknown when stored erythrocytes maximally express PS, but PS
expression probably occurs continuously, followed by vesicle formation. In a previous
study evaluating units of canine RBC concentrates, PS expression on the surface of
microparticles increased during storage.28 Therefore, if the PS-positive microparticles in
units of canine pRBCs were released from erythrocytes, then the PS expression on
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individual red blood cells would have minimal change during leukoreduction, storage and
transfusion.
In humans, Burger et al demonstrated an increased erythrocyte PS expression
during storage of blood products, but this expression was transient and associated with
increasing amounts of PS-positive vesicle formation. Additionally, the LR units were
stored for 42 days, twice as long as our study, and the PS expression only changed after
an overnight incubation at 37oC, to mimic the environment of red blood cells following a
transfusion.9 In our study, the units were subjected to 5 hours at room temperature
(approximately 21oC) to simulate the temperature change during a transfusion before the
erythrocytes enter the recipient, but we did not evaluate PS expression on erythrocytes at
a temperature that would mimic the body temperature of the recipient. It is possible that
with a longer storage time and greater erythrocyte incubation temperature, to mimic the
environment of transfused erythrocyte, we could have detected a change in PS expression
on RBCs. Although PS translocation is a well-described storage lesion in humans,9-11
due to unpredictable vesiculation and the difficulty in determining microparticle origin,
using PS expression as a marker for erythrocyte quality in units of canine pRBCs can be
unpredictable and difficult to interpret.
In a previous study performed in dogs, storage of units of pRBCs caused a
decrease in arachidonic acid concentration, followed by a progressive increase in the
concentration of eicosanoids inside the units.15 One possible explanation for these
changes in eicosanoids during storage was a decline of cell health, particularly in
leukocytes and platelets, leading to a decrease in cell viability and an increase in
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enzymatic conversion of arachidonic acid to the various eicosanoids. In humans, the prestorage removal of leukocytes and platelets via leukoreduction decreases the
concentrations of PGE2 and TXB2 in stored units of pRBCs.29 In contrast, in our study,
the removal of leukocytes and platelets prior to storage did not significantly decrease
eicosanoid concentrations.. At most sample time points in our study, eicosanoid
concentrations were similar between LR and non-LR units, suggesting that
leukoreduction may have minimal impact on the accumulation of eicosanoids in units of
canine pRBCs.
Compared to non-leukoreduced units, the passing of blood through the
leukoreduction filter prior to storage created an immediate and marked increase in TXB2
and PGF2α concentrations. The increase in TXB2 concentration is particularly concerning
because, as a potent platelet activator and vasoconstrictor, an increase in this eicosanoid
could have a significant impact on the hemodynamic stability of transfusion recipients.
This concern, however, may only be applicable to blood products that are leukoreduced
and immediately administered to the recipient because, during storage, TXB2
concentrations in LR units decreased to concentrations similar to non-LR units. It is
unknown for how long after leukoreduction TXB2 concentrations remain elevated but,
after 10 days of storage, the concentrations are similar to non-LR units.
A possible explanation for the increase in TXB2 concentration immediately
following leukoreduction is that platelets are activated as they adhere to the fibers within
the filter. In human blood products, based on platelet shape change and pseudopod
formation, platelets appear to become activated as they pass through leukoreduction
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filters.30 Once activated, platelets will increase expression of integrins needed for
aggregation, change shape to cover a greater surface area, empty the contents of granules,
and release arachidonic acid to be converted to thromboxane A2.31 After synthesis,
thromboxane A2 exhibits a very short half-life and is non-enzymatically decomposed to
the stable metabolite TXB2.32 While platelets are the primary source of thromboxane A2,
several other cells are capable of synthesizing this eicosanoid, including leukocytes and
endothelial cells.32,33 Even though the cyclooxygenase (COX)-2 enzyme has been
identified in canine platelets,34 COX-1 is the primary isoform in platelets, and probably
responsible for the increased synthesis of TXB2 in units of pRBCs. It is unknown how
elevated concentrations of TXB2 affect the patient, but the increased TXB2 associated
with leukoreduction and immediate transfusion may have the potential to adversely
impact the recipient.
In addition to TXB2, PGF2α also significantly increased immediately after
leukoreduction. Prostaglandin F2α, is synthesized via three pathways from PGE2, PGD2,
or PGH2 by PGE 9-ketoreductase, PGD 11-ketoreductase, or PGH 9-,11-endoperoxide
reductase, respectively.35 Collectively referred to as prostaglandin F synthases (PGFS),
these enzymes are expressed in numerous organs including the liver, lung, brain, kidneys
and uterus, but PGFS mRNA has also been identified in peripheral blood lymphocytes.36
The mechanism of increased PGF2α after leukoreduction in this study is unclear, but it is
possible that PGFS were released from lymphocytes activated during the filtration
process. Some studies have described leukocyte activation with the use of leukocyte
depletion filters,37-39 however, these findings were not consistently replicated in other
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leukoreduction studies.40-43 Furthermore, leukocyte rupture is possible with prolonged
filtration, resulting in free enzymes and other cellular components.44 Similar to TXB2,
the increase in PGF2α concentration following leukoreduction is particularly concerning
because PGF2α is associated with vasoconstriction and bronchoconstriction, which could
impact the hemodynamic stability of transfusion recipients.16
The decrease in TXB2 and PGF2α concentrations during storage could be
associated with the short half-life of these molecules. Prostanoid activity is usually short
lived, and catabolism of these molecules occurs rapidly and primarily through the
pulmonary circulation. Prostanoid catabolism involves several enzymes, particularly 15hydroxyprostaglandin dehydrogenase (15-PGDH), which results in oxidation of the 15OH group to the corresponding ketone.27,45,46 In addition to being found in high
concentrations in the lungs, 15-PGDH is located throughout the body, including a high
expression in leukocytes.47 Despite removal of the leukocyte population, the release of
15-PGDH from activated leukocytes at the time of leukoreduction may have contributed
to TXB2 and PGF2α catabolism.
Compared to our previous study,15 despite some similar trends, overall the
eicosanoid concentrations in this current study were significantly lower. One potential
explanations for these differences include quantity of cells within the unit. Unlike the
previous study which used greyhounds as donor dogs, our study used hound dogs which,
compared to greyhounds, have a lower percentage of circulating erythrocytes. The
average hematocrit from the dogs in the current study was 49.5%, while the average PCV
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in our previous study was 68%. The lower percentage of cells inside the units could have
contributed to this decrease in eicosanoid synthesis.
Biosynthesis of eicosanoids depends on the availability of arachidonic acid, which
is derived from membrane phospholipids by several enzymes, including phospholipase
A2. Once released, arachidonic acid can be metabolized by three main pathways: the
COX pathway that produces prostanoids, the lipoxygenase (LOX) pathway that produces
leukotrienes and lipoxins, and the P-450 epoxygenase pathway that produces epoxides.16
The erythrocyte membrane is a rich source of arachidonic acid, but lacks both the COX
and LOX enzymes, and therefore cannot produce the majority of eicosanoids.18 However,
the arachidonic acid-rich erythrocytes can contribute to eicosanoid synthesis via
transcellular biosynthesis, the cooperation among different cell types to produce
eicosanoids. During transcellular biosynthesis, one cell type can synthesize an
intermediate compound, through a primary oxidative enzyme, which is transferred to a
neighboring cell to complete the final synthesis.
In our study, the only eicosanoid that increased in concentration during storage or
simulated transfusion was 6-keto-PGF1α. This was similar to a previous study that
identified an increase in 6-keto-PGF1α concentration in units of canine pRBCs during
storage and transfusion.15 This prostaglandin is produced via non-enzymatic conversion
from PGI2, which is derived by the vascular epithelium or lymphocytes.16 Interestingly,
after the removal of the leukocytes and platelet via leukoreduction, the predominate cell
type expected to be remaining in the unit is the erythrocyte, which is not capable of
synthesizing prostanoids. Therefore, we presume that, despite leukoreduction,
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components within units of pRBCs contributed to increased concentrations of 6-ketoPGF1α via a process similar to transcellular biosynthesis. Specifically, arachidonic acid
could be derived from the rich phospholipid bilayer of erythrocytes, and converted to
prostacyclin via the COX-2 enzymes found in other cellular components within units of
pRBCs.
While it is unknown how the accumulation of eicosanoids in units of pRBCs will
affect physiologic responses within the transfusion recipient, considering the functions of
these molecules, the administration of blood products with elevated concentrations of
eicosanoids could have detrimental effects. For example, thromboxane promotes platelet
aggregation, vasoconstriction and bronchoconstriction, all of which may adversely affect
hypercoagulable and hypertensive patients.16 Thromboxane can also enhance the
production of IL-8, a pro-inflammatory cytokine and potent neutrophil
chemoattractant48,49 and, therefore, may promote transfusion-associated inflammatory
responses. Additionally, transfusing blood products with high concentrations of
prostacyclin, which inhibits platelet aggregation and promotes vasodilation,16 may further
exacerbate complications associated with systemic hypotension in critical patients.
Although our study did not detect significant accumulation of eicosanoids, further studies
under a range of different storage conditions are needed to determine if eicosanoids can
accumulate in storage to a concentration significant enough to cause adverse effects in
the recipient.
To determine the effectiveness of leukoreduction, leukocyte and platelet counts
were performed immediately before and after leukoreduction. The filter was effective at
47

removing all leukocytes, but the filters were less effective at removing platelets prior to
storage. Seven units had a post-filter platelet count of less than 20 K/µL, but one unit had
137 K/µL platelets post filtration, a 60% reduction in platelet count compared to the prefiltration sample. This elevated platelet count in the LR units could have altered the
results of our study. If the eicosanoid and phosphatidylserine results from this unit were
removed from our analyses, however, there was no major change in overall results, and
the results from this unit were therefore included in our final analyses.
There were several limitations with this study. One limitation was not using a
transfusion administration set during the simulated transfusion. With the use of a
transfusion administration set and the passing of blood through an additional in-line
administration filter, additional changes could have developed in either eicosanoid
concentrations or PS expression. Another limitation of this study was the storage length
of 21 days. Compared to other studies investigating storage lesions, a 21-day storage
period may have been too short of time to detect a change in eicosanoid concentration or
PS expression, and it is possible that a longer storage duration would be associated with
greater changes. Additionally, our study evaluated the prostanoids derived from the COX
pathway and LTB4 produced by the LOX pathway, but the epoxides synthesized by the
P-450 pathway were not measured. Even though leukoreduction did not significant
reduce the eicosanoids measured in this study, it is possible that the removal of
leukocytes and platelets prior to storage could have reduced vasoactive epoxides.
Finally, despite a sample size calculation that suggested that 8 dogs would provide ample
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power for this study, including more dogs in this study may have provided additional
results.
Our study demonstrated that PS expression on the surface of erythrocytes was not
affected by leukoreduction or storage duration. Additionally, the passage of blood
through a leukoreduction filter causes an immediate and dramatic increase in TXB2 and
PGF2α concentrations, but these concentrations then decrease during subsequent storage.
Despite leukoreduction, the concentration of 6-keto-PGF1α continued to increase during
storage and simulated transfusion. Overall, when compared to non-LR units, the addition
of a leukoreduction step prior to storage had a minimal impact on the accumulation of
eicosanoids in canine units of pRBCs. While leukoreduction may be beneficial in other
aspects of transfusion medicine, based on the results in this study, using leukoreduction
to decrease PS expression and eicosanoid concentrations does not appear to be effective.
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Footnotes
a. Teruflex Optisol Triple Collection Blood Bag, Terumo Corporation, Tokyo, Japan
b. Imuflex-WB-RP Blood Bag with integral whole blood leukocyte reduction filter,
Terumo Corporation, Tokyo, Japan
c. Abbott Cell-Dyn® 3700, Abbott Laboratories, Abbott Park, IL
d. Bovine Serum Albumin, Sigma-Aldrich, St. Louis, MO
e. FITC Annexin V/Dead Cell Apoptosis Kit, Life Technologies, Grand Island, NY
f. FACSCalibur, BD Biosciences, San Jose, CA
g. CellQuest Pro software, BD Biosciences, San Jose, CA
h. HyperSep Retain PEP 60 mg, 1mL, Thermo Fisher Scientific, Waltham, MA
i. Acquity UPLC BEH C18 column, Waters Corporation, Milford, MA
j. TSQ Quantum Access Max, Thermo Fisher Scientific Inc, San Jose, CA
k. Xcaliber software, ThermoFisher Scientific Inc, San Jose, CA
l. SAS for Windows version 9.4, SAS Institute, Inc., Cary, NC
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Figure 3.1 Leukocyte (A) and platelet (B) counts prior to and after
leukoreduction. LR, Leukoreduced

55

Table 3.1 Based on flow cytometric analysis, the MFI (mean ± standard deviation) of
canine erythrocyte PS expression, with and without leukoreduction, at collection
(donation) and after various lengths of storage (pre-transfusion) and after a simulated
transfusion (post-transfusion).
Sample
Non-LR Units of pRBCs
LR Units of pRBCs
Day 0 - Donation

7.74±1.04

7.57±0.83

Day 10 – Pre-transfusion

7.28±1.10

7.21±0.68

Day 10 – Post transfusion

7.13±0.93

6.99±1.25

Day 21 – Pre transfusion

7.88±0.93

7.85±0.98

Day 21 – Post transfusion

7.42±1.59

7.77±1.28

MFI, median fluorescence intensity; PS, phosphatidylserine; LR, leukoreduced
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LR

123.1±44.6†

7.8±11.3†

TXB2

LTB4

PGF1α

9.3±8.7

10±2.5

1.2±0.5

1.8±0.9†

0.2±0.3†

PGF2α

0.7±0.4

0.3±0.2

0.5±1

PGD2

1.0±0.7

0.6±1.3

6-keto-

Non-LR

23.7±28.9

5.9±2.2*

34±45.4

0.4±0.3

0.7±1

0.8±1.2

15.9±5.2

6.2±2.4*

47.3±19.4*

0.7±0.3*

0.1±0.1

0.2±0.1

783.7±427

LR

Day 10 - Pre transfusion

735.9±258.2 586.5±277.2 398.3±162.8

Non-LR

Day 0 - Donation

PGE2

AA

Eicosanoid

LR

Non-LR

LR

transfusion

Day 21 - Pre

Non-LR

LR

Day 21 - Post transfusion
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19.7±29.4

5.7±2.4*

60±127.8

0.7±0.9

0.9±2

1.0±2.4

16±4.9

8.4±1.3*

64.4±22.4

0.9±0.4*

0.1±0.1

0.3±0.2

18.7±13.7

4.8±1.1*

12.1±16

0.1±0.1

0.4±0.5

0.6±0.6

14.2±5.5

5.3±1.1*

21.5±9.6*

0.4±0.1*

0.1±0.1

0.1±0.1

17.3±10.9

5.5±1.5*

10.3±12.1

0.2±0.2

0.4±0.5

0.4±0.5

17.6±9.4

6.4±1.5*

26.2±11.2*

0.4±0.3*

0.2±0.3

0.3±0.4

413.7±282.4 715.6±290 431.9±246 544±357.7 578.9±493.2 514.5±285.7

Non-LR

transfusion

Day 10 – Post

nM, nanomolar; pRBCs, packed red blood cells; Non-LR, non-leukoreduced; LR, leukoreduced; AA, arachidonic acid; PGE2 prostaglandin E2; PGD2,
prostaglandin D2; PGF2α, prostaglandin F2α; TXB2 thromboxane B2; 6-keto-PGF1α, 6-keto-prostaglandin F1α; LTB4, leukotriene B4.
Results labeled “*” illustrate significant (p≤0.05) differences from the respective donation sample.
Results labeled “†” illustrate significant (p≤0.05) differences between Non-LR and LR samples at the same time point.

Table 3.2 The eicosanoid concentration (nM) (mean ± standard deviation) in units of canine pRBCs, with and without
leukoreduction, at collection (donation) and after various lengths of storage (pre-transfusion) and after a simulated transfusion
(post-transfusion).

CHAPTER IV
CONCLUSION
In this study, units of packed red blood cells were evaluated for changes in both
phosphatidylserine expression and eicosanoid concentrations in response to
leukoreduction and various storage times. The results of our study demonstrate that, in
units of canine pRBCs, leukoreduction and storage have minimal impact on erythrocyte
PS expression, but alter concentrations of some eicosanoids. Data obtained from this
study have resulted in new ideas regarding future directions for research surrounding
storage lesions.
Significant changes in PS expression on erythrocytes were not noted in this study.
As previously mentioned, similar findings have been reported in human studies, in which
only a small percentage of PS-positive erythrocytes (3.5 to 4.5%) were detected after
prolonged storage times of up to 7 weeks using similar techniques.1-4 One possible
explanation for why an increase in RBC PS expression was not detected is that the PS
positive portions of the erythrocyte membrane were released from the cell, becoming PS
expressing microparticles in the unit. In stored units of human pRBCs, erythrocytes can
undergo vesiculation to return to a PS-negative state by shedding PS-containing
vesicles.5,6 It is unknown when stored canine erythrocytes maximally express PS, but PS
expression may occur continuously, followed by vesicle formation. In a previous study
evaluating units of canine RBC concentrates, PS expression on the surface of
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microparticles increased during storage.7 Therefore, if the PS-positive microparticles in
units of canine pRBCs were released from erythrocytes, then the PS expression on
individual red blood cells would have minimal change during leukoreduction, storage and
transfusion. Future studies investigating both erythrocyte and microparticle PS
expression concurrently in units of canine packed red blood cells would be helpful in
clarifying this process.
In humans, Burger et al demonstrated an increased erythrocyte PS expression
during storage of blood products, but this expression was transient and associated with
increasing amounts of PS-positive vesicle formation. Additionally, the leukoreduced
units were stored for 42 days, twice as long as our study, and the PS expression only
changed after an overnight incubation at 37oC, to mimic the environment of red blood
cells following a transfusion.5 In our study, the units were subjected to 5 hours at room
temperature (approximately 21oC) to simulate the temperature change during a
transfusion before the erythrocytes enter the recipient, but we did not evaluate PS
expression on erythrocytes at a temperature that would mimic the body temperature of
the recipient. Future studies that incorporate a longer storage time and greater erythrocyte
incubation temperature, to mimic the environment of transfused erythrocyte, are needed
to potentially detect a change in PS expression on RBCs. Although PS translocation is a
well-described storage lesion in humans,1,5,8 due to unpredictable vesiculation and the
difficulty in determining microparticle origin, using PS expression as a marker for
erythrocyte quality in units of canine pRBCs can be unpredictable and difficult to
interpret.
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In humans, the pre-storage removal of leukocytes and platelets via leukoreduction
decreases the concentrations of PGE2 and TXB2 in stored units of pRBCs.9 In contrast, in
our study, the removal of leukocytes and platelets prior to storage did not significantly
decrease eicosanoid concentrations. Alternatively, we observed a marked increase,
specifically in TXB2, immediately post-leukoreduction, which raises concern regarding
hemodynamic effects in the recipient. Furthermore, storage resulted in an increase in 6keto-PGF1α, a stable prostacyclin metabolite. Transfusing blood products with high
concentrations of prostacyclin, which inhibits platelet aggregation and promotes
vasodilation, may further exacerbate complications associated with systemic hypotension
in critical patients. However, it is unknown if the metabolites of thromboxane and
prostacyclin are representative of the biologically active compound. Futhermore, it is
unknown if these metabolites would have an effect on the recipient if transfused in high
concentrations. Further studies under a range of different storage conditions are needed to
determine if eicosanoids can accumulate in storage to a concentration significant enough
to cause adverse effects in the recipient.
The exploration of the clinical significance of storage lesions in veterinary
medicine is quite limited. Large observational studies of human patients, especially those
with trauma, after cardiac surgery, or in a pediatric intensive care unit, found associations
between transfusions of older PRBCs and increased rates of sepsis, multiple organ
dysfunction syndrome, mortality or some combination of these.10-12 Such studies raise
concerns regarding whether older pRBC units should be used in critically ill patient
populations. In a retrospective study summarizing data from 3,095 dogs on the
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association of pRBC storage duration on morbidity and mortality, the age of transfused
pRBCs did not contribute to mortality in the general canine population, although there
may be associations with multiple organ dysfunction and coagulopathies.13 Additionally,
administration of older stored autologous RBCs has been shown to induce an
inflammatory response in healthy dogs.14
In this study, we identified changes in canine pRBC units in response to
leukoreduction and storage, however, we do not know if these changes would
significantly affect patients to which these units were transfused. The next step in our
research should involve prospective investigation of the recipient to which stored
leukoreduced and non-leukoreduced allogenic units transfused. Subsequent monitoring
of the recipient along with analysis of blood samples for various procoagulant and
inflammatory markers would provide very useful information for veterinary transfusion
medicine.
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